Exercise Targeting Cognitive Impairment in Parkinson's Disease

Exercise Targeting Cognitive Impairment in Parkinson's Disease

The aim of this application is to compare and elucidate the effects of skill-based versus aerobic exercise versus control on mild cognitive impairment (MCI) of the executive function (EF) subtype in Parkinson's disease (PD); we hypothesize that skill-based exercise will result in the greatest improvement in EF and lead to modification of underlying neural substrates.

Mild cognitive impairment (MCI), particularly of the executive function (EF) subtype, is common in Parkinson's disease (PD) and transitions to dementia, increased fall risk, and poor quality of life. EF is a set of processes that include mental flexibility and attention that are needed to learn and optimize performance of complex cognitive and motor skills. Such skills include the ability to generalize task performance under different conditions (context processing) and to perform two tasks simultaneously termed dual-task (DT) performance. Deficits in EF lead to problems in daily functioning and loss of independence and create psychosocial and economic burdens on patients and caregivers and stakeholders including health care providers. There is currently no effective treatment in PD to address EF deficits. Our animal and clinical studies in PD demonstrate that skilled exercise facilitates neuroplasticity of the basal ganglia (BG), a brain region sub-serving EF and supports the hypothesis that exercise will reverse EF deficits in PD. Furthermore, recent studies in healthy aging support that skill-based exercise that specifically promotes motor skill fitness (MSF), compared with aerobic exercise that promotes cardiovascular fitness (CF), has a greater impact on EF and related BG circuits. The aim of this application is to compare and elucidate the effects of skill-based versus aerobic exercise versus control on MCI of the EF subtype in PD; we hypothesize that skill-based exercise will result in the greatest improvement in EF and lead to modification of underlying neural substrates.

Inclusion Criteria:

• willing and able to provide informed consent
• confirmed diagnosis of idiopathic PD based on the United Kingdom Brain Bank criteria
• Mild cognitive impairment (Level II criteria Movement Disorder Task Force)
• medically eligible for MRI imaging
• able to provide a written medical clearance from their primary physician to participate in exercise
• stable PD medications for 3 months

Exclusion Criteria:

• a Hoehn & Yahr staging greater than 2.5 at screening
• severe cardiac disease (New York Heart Association classification IIIV)
• history of an abnormal stress test
• clinically significant medical or psychiatric illness
• electrically, magnetically, or mechanically activated implant (such as cardiac pacemakers or intracerebral vascular clip)
• metal in any part of the body including metal injury to the eye
• past history of brain lesions (such as stroke)
• seizures or unexplained spells of loss of consciousness
• family history of epilepsy
• physical therapy within 6 months of the study
• symptomatic orthostatic hypotension at the screening visit
• orthopedic and other movement-influencing diseases such as arthritis or total hip joint replacement
• requirement for central nervous system active therapies (e.g. hypnotics, antidepressants, anxiolytics)
• moderate or severe depression or apathy using the Geriatric depression scale and Apathy scale
• taking anticholinesterase inhibitors
• taking anticholinergic medication
• PD dementia
• Colorblindness